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FluorescenceThe nucleocapsidic protein (NC) of orthoretroviruses has been considered as a promising target for
antiretroviral drugs. Compounds, including zinc ejectors and metal derivatives capable to substitute
the zinc ion in the nucleocapsidic zinc fingers, have been described. Auranofin, a gold(I) drug used for
the treatment of rheumatoid arthritis, restricts the viral reservoir in the monkey AIDS model and induces
containment of viral load following anti-retroviral therapy suspension. Here is reported a study of the
interactions of auranofin with two synthetic CCHC-type peptides corresponding to the C-terminal zinc
finger of the HIV-2 NC protein from two different isolates, using spectroscopic techniques and mass spec-
trometry. Both apopeptides interact very slowly with auranofin forming an Au-peptide complex. In con-
trast, as shown by mass spectrometry, the zinc-bound peptides interact on a shorter time-scale by
forming an Et3P-Au-peptide complex and an Au-peptide complex. The two peptides show kinetic differ-
ences in the formation of zinc complexes, in Zn2+ binding constants as well in Zn2+ displacement by Au+.
 2016 Elsevier B.V. All rights reserved.1. Introduction
Lentiviruses constitute a genus of retroviridae family which
includes several viruses (HIV-1, HIV2, SIV, Visna virus, FIV, EIAV,
CAEV, BIV, etc.) infecting diverse species. They are host-specific
viruses that cause slowly progressive diseases in their hosts.
The nucleocapsid proteins (NC) of orthoretroviruses are small
(<100 amino acids), highly basic nucleic acid binding proteins con-
taining either one (in Gammaretroviruses) or two (in all other
retroviral or Orthoretrovirinae Subfamilies) strictly conserved zinc
fingers with sequence C-X2-C-X4-H-X4-C (CCHC). In all retroviral
zinc finger proteins, the spacing of the zinc-binding residues is
extremely conserved and so are the surrounding sequences within
a particular retroviral species, as demonstrated, for instance, by
various human immunodeficiency virus type-1 (HIV-1) and type-
2 (HIV-2) sequences. Zinc finger proteins form stable structureswith the NH2- and COOH-terminal regions that are unstructured
when the NC is not bound to nucleic acids [1].
In retroviruses, NC is synthesized as a functional domain of the
Gag precursor. The mature NC is cleaved by a series of retroviral
proteases during virus assembly in the infected cells. In orthoretro-
viruses, three main structural proteins are produced from Gag:
matrix (MA), capsid (CA), and nucleocapsid (NC), as well as addi-
tional retrovirus-specific peptides. NC is required for viral replica-
tion, and genetic analyses have demonstrated that even minor
mutations can affect the virus assembly step by disrupting either
the genomic RNA packaging or the formation of infectious virus
particles [2]. NC is a key component of virus assembly processes.
It is responsible for binding to the RNA scaffold, thereby facilitating
the interactions of other regions of Gag with one another and with
cellular membranes, and it is required for the recognition and
packaging of the RNA genome. Moreover, NC can cause defects in
RNA dimer maturation, reverse transcription and integration [3].
Due to its key role in viral replication, NC has been indicated as a
promising target for antiretroviral drugs and compounds, including
zinc ejectors, targeting the retroviral HIV-1 NCp7 [4–6]. It has also
been suggested that metal compounds could substitute the zinc
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derivatives [7,8].
Gold compounds (sodium aurothiomalate, aurothioglucose,
auranofin) are thiol-reactive substances containing gold (I)
(Au1+)-containing thiol-reactive substances used for the treatment
of rheumatoid arthritis and other inflammatory disorders. The
mode of action of these chemicals is due to reactions with cysteine
(Cys) residues [9]. Gold (I) compounds alter gene expression, their
anti-inflammatory activities likely involving interactions with Cys-
dependent transcription factors [10,11]. In addition, it is known
that gold fingers are formed when Au (I) interacts with Cys resi-
dues in zinc finger model peptides containing different CCCC,
CCHH and CCHC motifs [12].
Auranofin is toxic towards parasites, cancer cells and leukemia
cells [13], and is believed to act through the inhibition of different
reduction/oxidation (redox) enzymes such as thioredoxin reduc-
tase [14,15], glutathione-S-transferase [16] and the zinc finger pro-
tein poly(adenosine diphosphate ribose)polymerase-1, PARP-1
[17]. Moreover, auranofin is known to restrict the viral reservoir
in the monkey AIDS model and to induce containment of viral load
following anti-retroviral therapy suspension [18].
In this study, we report the interactions of auranofin with the C-
terminal zinc finger of the HIV-2 NC from two different isolates
using spectroscopic techniques and mass spectrometry. The analy-
sis of two divergent zinc finger CCHC peptides revealed the impor-
tance of the amino acid sequence effects in the interaction with
auranofin and may help to clarify the antiviral activity of auranofin.
To the best of our knowledge, this is the first study on the interac-
tion of auranofin with CCHC zinc fingers.2. Materials and methods
2.1. Phylogenetic analysis
Simian immunodeficiency viruses (SIV) and HIV-2 Gag
sequences were retrieved from the Los Alamos National Laboratory
(LANL) HIV sequences database (http://www.hiv.lanl.gov). Multi-
ple sequence alignment was performed on amino acid sequences
using MUSCLE [19]. PAL2NAL [20] was used to obtain the corre-
sponding nucleotide alignment, which was subsequently edited
in SeaView v. 4 [21]. The best model fitting the data was identified
in jModelTest 2.1.7 [22]; the choice was based on a majority-rule
consensus of the implemented statistics. Maximum likelihood
phylogenetic inference was carried out on first and second codon
positions under the TPM2uf +C4 (k = 010212) best-fitting model
in PhyML v. 3 [23]. Tree-space was searched using the subtree
pruning and regrafting (SPR) heuristic (BioNJ and five random
starting trees). The aBayes statistic was used to assess branch sup-
port [24].Scheme 1. Chemical structures of: A) auranofin; B) PAR and C) TCEP.2.2. Samples
All reagents used in the present study were reagent grade and
used without further purification. Apopeptides were produced by
Fmoc-solid-phase peptide synthesis technology (Inbios srl, Naples,
Italy) and correspond to residues 23–49 of HIV-2 NCp8 of two dif-
ferent isolates: respectively, peptide A (RAPRRQGCWKCGKP-
GHIMTNCPDRQAG) corresponds to isolate ROD (country Senegal,
subtype A, GenBank accession M15390) and peptide H
(KAPRRQGCWKCEKPGHNMASCPETKVG) to isolate 96FR12034
(country France, subtype U (formerly group H), GenBank accession
AY530889). As received, the synthetic peptides had purity higher
than 98%; the MALDI molecular masses given by the supplier were
3024.5 for peptide A and 2999.5 for peptide H, respectively. Aura-
nofin (1-Thio-b-D-glucopyranosatotriethylphosphine gold-2,3,4,6-tetraacetate, purity P98%), TCEP (Tris(2-carboxyethyl)phosphine
hydrochloride, purity P98%) and PAR (4-(pyridyl-2-azo)-resorci-
nol, purityP95%) were purchased from Sigma-Aldrich (Scheme 1).
2.3. Circular dichroism spectroscopy
Circular dichroism (CD) spectra were recorded on a Jasco J-600
spectropolarimeter using a 0.1 cm path-length cylindrical quartz
cell. Peptide samples at 58.3 lM concentration in a 10 mM sodium
phosphate buffer at pH 7.2 were reduced with TCEP (peptide:TCEP
ratio = 1:3.6). ZnCl2 was dissolved in water at concentration of
50 mM and added to peptides (peptide:ZnCl2 ratio = 1:1.2)
30 min before recording spectra. Auranofin was dissolved in
methanol at concentration of 6.5 mM and added to peptides (pep-
tide:auranofin ratio = 1:1.2). Data were acquired at 20 C and were
baseline corrected by subtraction of buffer/TCEP or buffer/TCEP/
ZnCl2 or buffer/TCEP/auranofin. In each case, the final spectrum
is the sum of 16 separate spectra with a step resolution of
0.1 nm, a 2-s time constant, a 50 nmmin1 scan speed, a 1 nm
bandwidth and a 20 mdg sensitivity.
2.4. UV–vis spectroscopy
The solutions containing PAR (25 lM), ZnCl2 (7.5 lM) and
reduced peptides (58.3 lM) were prepared and used to record
absorption spectra in the range 350–600 nm using a CARY-5E-
Spectrophotometer. Identical conditions were adopted when aura-
nofin (to a final concentration of 12 lM) was added to PAR-pep-
tide-Zn complexes. The experiments were performed at 20 C.
2.5. Intrinsic fluorescence measurements
The intrinsic tryptophan fluorescence of reduced peptides
(3 lM) was measured in sodium phosphate buffer (10 mM, pH
7.2) alone or in the presence of ZnCl2 (peptide:ZnCl2 ratio = 1:1.2)
or auranofin (peptide:auranofin ratio = 1:1.2). The experiments
were performed at 20 C with a thermostated Agilent Technologies
Cary Eclipse Fluorescence Spectrophotometer. The excitation
wavelength was set at 295 nm and emission was scanned over
the range 300–450 nm, with scan rate of 30 nm/min, averaging
time 1 s and data interval 0.5 nm.
The method employed by Mély et al. was used for the determi-
nation of the Zn2+ binding constants where the metal complexant
EDTA was used ‘‘to buffer very low free Zn2+ concentrations”
[25]. Fluorimetric titrations were performed by adding increasing
concentrations of zinc chloride to a given peptide in the presence
of 1 mM EDTA. After each addition of 1 ll of ZnCl2 5 mM, the fluo-
rescence intensity change was monitored at the maximum emis-
sion wavelength (353 nm) for at least 15 min to ensure that
equilibrium was reached. From the fluorimetric titrations the aver-
age number m of Zn2+ moles bound per peptide mole was evaluated
by m = (I  I0)/(It  I0), where I is the fluorescence measured after
each zinc addition, I0 the fluorescence of the apopeptide and It that
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the results of at least three independent determinations performed
under the same experimental conditions.2.6. Mass spectrometry analyses
An aliquot of auranofin, previously dissolved in methanol to a
final concentration of 6.5 mM was directly submitted to MALDI-
MS analysis.
Each peptide was dissolved in ammonium acetate (5 mM, pH 7)
to a final concentration of 300 lM.
Auranofin-peptide complexes were prepared by incubation of
auranofin with each peptide solution to a peptide:auranofin molar
ratio of 1:1.2. Prior to auranofin addition, the non-thiol reducing
agent TCEP was added to each peptide solution to a molar ratio
peptide:TCEP of 1:3.6 in order to prevent oxidation of cysteine resi-
dues. The ESI-MS analysis was carried out on a time course basis by
recording spectra at different incubation times (0 h, 24 h, 48 h,
1 week and 1 month).
In order to study the displacement of the zinc ion from the pep-
tides upon addition of the auranofin to the peptide-TCEP mixture,
an aliquot of ZnCl2, previously dissolved in H2O to a final concen-
tration of 100 mM, was added to a molar ratio peptide:Zn of
1:1.2. Aliquots of the peptide-Zn complexes were submitted to
ESI-MS analysis after 1 h of incubation. Afterwards, an aliquot of
auranofin was added to peptide-TCEP-ZnCl2 mixture (final molar
ratio peptide:auranofin = 1:1.2) and aliquots of the complexes
were submitted to ESI-MS analysis at different incubation times
(10 min, 1 h, 24 h, 4 days, 1 week, 2 weeks and 3 weeks).
MALDI-MS analyses were carried out on a 4800 plus MALDI
TOF-TOF Analyzer mass spectrometer (AB Sciex) equipped with a
reflectron analyser and used in delayed extraction mode with
4000 Series Explorer v3.5 software. Aliquot of 0.5 ll of the sample
was mixed with an equal volume of a-cyano-4-hydroxycynnamic
acid as matrix (10 mg/ml in 0.2% TFA in 70% acetonitrile), applied
to the metallic sample plate and air dried. Mass calibration was
performed by using the standard mixture provided by manufac-
turer. MALDI-MS spectra were acquired over a mass range of
600–5000m/z in the positive-ion reflector mode. MS spectra were
acquired and elaborated using the software provided by the
manufacturer.
ESI-MS analyses were performed on a Quattro micro mass spec-
trometer (Waters) equipped with a triple quadrupole and an elec-
trospray source. Sample solutions were introduced into the
electrospray ion source by a syringe pump. Calibration was per-
formed using multiply charged ions from a separate introduction
of horse heart myoglobin. Spectra were acquired in a mass range
of 500–1200 m/z and elaborated using the software provided by
the manufacturer. Molecular masses are given as average values.Sequences          
      NCp8  RAPRRQGCWKCGKTGHVMAKCPERQAG
Peptide A RAPRRQGCWKCGKPGHIMTNCPDRQAG
Peptide H KAPRRQGCWKCEKPGHNMASCPETKVG 
Fig. 1. Primary structures of peptide A (GenBank accession M15390) and peptide H
(GenBank accession AY530889). In boldface and underlined are represented
residues different from the (23–49) HIV-2 NCp8 sequence studied by Matsui et al.
(GenBank Accession number M30895) [27].2.7. NMR spectroscopy
Peptides were dissolved in 10 mM sodium phosphate buffer-
20% D2O (pH 7.2) to give a final concentration of approximately
1 mM peptide. TCEP was added to prevent the oxidation of the cys-
teine residues (peptide:TCEP ratio = 1:3.6). 1.2 equivalents of ZnCl2
were then added to form the complexes.
The auranofin-peptide complexes were prepared by dissolving
the peptide in 10 mM sodium phosphate buffer-20% D2O (pH 7.2)
with TCEP and then adding auranofin in slight excess (1.2 equiva-
lents) with respect to peptide concentration.
1H NMR data were collected using a VARIAN Unity Inova
500 MHz spectrometer with sample at 298 K. Chemical shifts were
referenced to the methyl resonance signal of TSP (3-(trimethylsi-
lyl)propanoic acid) used as internal standard.2D TOCSY, ROESY and NOESY experiments were recorded in
phase sensitive mode using different mixing times (65 and 80 ms
for TOCSY; 200, 300 and 400 ms for ROESY; 100, 150 and 250 ms
for NOESY experiments). The number of transients were 32 for
both TOCSY and ROESY with 256 experiments; in NOESY experi-
ments 64 transients were acquired for 512 experiments. The spec-
tral width was 5989 Hz in both dimensions. In all the experiments
the water signal was suppressed by presaturation or with a dpfgse
pulse sequence.3. Results
3.1. Choice of the peptides for spectroscopic studies
Both HIV-1 and HIV-2 exhibit considerable genetic variation,
which consequently has been used to classify isolates into genetic
subtypes, formerly defined as groups, designated A to G. In the
LANL HIV Sequence Database the majority of HIV-2 sequences
belong to subtypes A and B. Compared to HIV-1, only a small num-
ber of HIV-2 complete genomes have been determined (http://
www.hiv.lanl.gov/).
Two strategies were used to select the peptides: (i) the phyloge-
netic analysis of the genes coding for the Gag protein, and (ii) the
sequence divergence at the amino acid level with respect to the
C-terminal zinc finger of NCp8.
Molecular phylogenetic analysis was carried out on a dataset of
27 HIV-2 Gag-polyprotein and 16 SIV Gag homologs. Maximum
likelihood inference was carried out on first and second codon
positions under the best-fitting evolutionary model (see Section 2
and Fig. S1, Supplementary information). Two sequences were
selected: peptide A (GenBank accession M15390) in the HIV-2 sub-
type A clade, which comprised also NCp8, and peptide H (GenBank
accession AY530889) belonging to the divergent subtype U. As to
sequence divergence, peptide A and H differ at 5 and 8 amino acid
residues, respectively, compared to the NCp8 sequence (GenBank
accession M30895) studied by Matsui et al. [27] (Fig. 1). Peptide
A belongs to the most infectious and diffuse subtype A, whereas
peptide H belongs to the subtype U and was identified in France
from a patient of West African origin, formerly defined as lineage
H [28].3.2. CD analysis of the zinc finger peptides
The effects of Zn2+ and Au+ on secondary structures of peptide A
(Fig. 2A) and peptide H (Fig. 2B) were investigated by CD spec-
troscopy. CD spectra were recorded for apopeptide, peptide-Zn
complex (immediately and after 2 h) and peptide-auranofin com-
plex (immediately, after 24 h and after 5 days).
CD spectra of the peptides in absence of zinc are compatible
with random coil conformations. The spectra of both peptide-Zn
complexes show a pronounced less negative ellipticity with
respect to the free peptide with no shift of the minimum in the
Fig. 2. A) CD spectra of peptide A: apopeptide (r); peptide plus Zn2+ immediately (j), after 2 h (N), plus auranofin immediately (x) and after 24 h (x); peptide plus auranofin
immediately (d), after 24 h (+) and after 5 days (-). B) The same measurements were performed also on peptide H. The data were expressed in terms of the molar ellipticity.
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minimum in the spectrum of peptide H.
These findings indicate that the structures are more ordered in
presence of zinc. Much less substantial secondary structure change
was observed for both peptides in the presence of auranofin.
Lastly, the effect of auranofin on the peptide-Zn complexes was
monitored. This led to a change in spectrum of peptide A, but no
substantial change was observed in the spectrum of peptide H. This
could be indicative of an overall modification of the zinc finger
structure of peptide A due to Au(I) binding.3.3. UV–visible spectroscopic investigation
We used PAR to qualitatively confirm zinc ejection from the
CCHC nucleocapsid zinc finger [8]. PAR is a tridentate ligand form-
ing ML2 type complexes with Zn(II) and other transition metals and
is used to measure micromolar concentrations of these metals [29].
Free PAR absorbs at 410 nmwhereas the PAR2-Zn complex shows
an absorption maximum at 500 nm. The most important physic-
ochemical parameters of this highly used chromogenic chelator
have been recently updated [30].
334 M.A. Castiglione Morelli et al. / Inorganica Chimica Acta 453 (2016) 330–338In order to verify that auranofin does not interact with PAR and
that it is not able to displace zinc from PAR, preliminary tests were
carried out at the same experimental conditions used in presence
of peptides: no interference was observed in the PAR2-Zn absorp-
tion spectrum due to auranofin and/or TCEP.
We next assessed the metal binding properties of both peptides
by displacing zinc from PAR in competition assays. Peptide H was
able to displace zinc ions from the PAR2-Zn complex although to a
lesser extent than EDTA. In fact, when added (peptide/ZnCl2Fig. 3. A) Absorption spectrum of 25 lM PAR alone (–), with 7.5 lM Zn2+ () and 58.3
18 h (--) and 6 days (–) after the addition of auranofin. B) The same measurements weratio = 1:1.2) to a solution containing the PAR2-Zn complex, pep-
tide H lowered the absorbance maximum at 500 nm (Fig. 3B).
Addition of auranofin (peptide/auranofin = 1:1.2 ratio) to a solution
containing the peptide H-Zn complex and PAR, led to an increase of
the PAR2-Zn absorbance maximum. This indicates that auranofin is
complexed with peptide H and therefore zinc is again accessible for
forming the PAR2-Zn complex. Thus, auranofin is able to displace
zinc from peptide H-Zn complex, at least in these experimental
conditions.lM peptide A (- -) in phosphate buffer pH 7.2 at 25 C. Spectra were also taken at
re performed also on peptide H.
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when PAR is present, therefore auranofin seems not to be active
(Fig. 3A). Indeed, the absorbance-maximum at 500 nm was not
modified. Noteworthy, the spectra of peptides A and H, after an
incubation time of 6 days with auranofin (Figs. 3A, B and S2), are
nearly identical. This finding seems to indicate that, as described
for peptide H, similar mechanisms of complex formation and dis-
placement could be also valid for peptide A, although with differ-
ent kinetics.Fig. 4. Intrinsic fluorescence spectra (kexc = 295 nm) of: A) peptide A and B) peptide H in
21 h (-).3.4. Fluorescence spectroscopy investigation
To monitor the binding of zinc to peptides we used the fluores-
cence of the single naturally occurring tryptophan (Trp) at position
31. The fluorescence increases upon addition of Zn(II) and the max-
imum emission wavelength shifts from 351 to 338 nm (Fig. 4). This
blue-shifted emission is typical of Trp residues in apolar environ-
ments while protein unfolding leads almost always to a red shift
[31].the absence (–) and presence of Zn (II) (..) and auranofin immediately (- -) and after
336 M.A. Castiglione Morelli et al. / Inorganica Chimica Acta 453 (2016) 330–338The method employed by Mély et al. [25] was used for the eval-
uation of the Zn2+ binding constants. The fluorescence quantum
yields of both peptide A and peptide H were observed to increase
linearly with sub-stoichiometric additions of zinc (data not
shown). At pH 7.2 the conditional zinc binding constants of peptide
A and peptide H were 5.94 ± 0.85  1014 M1 and 8.61 ± 0.61 
1014 M1, respectively. These constants support the qualitative
data obtained by absorption spectroscopy of different zinc binding
of peptide H in comparison with peptide A (see above).
Furthermore, the intrinsic fluorescence of Trp31 was also used to
assess qualitatively the susceptibility of the Zn(II)-peptide com-
plexes to Au(I) presence. The addition of auranofin has a markedFig. 5. ESI MS spectra of: (A) peptide A and (B) peptide H (300 lM peptide in 5 mM ammo
time with auranofin (molar ratio peptide/auranofin = 1:1.2). The MW values of all species
of the figure.effect on peptide A where the fluorescence intensity sharply
increases (by about 1.5-fold) and decreases noticeably after 21 h
(by about 2.3-fold) (Fig. 4A). In contrast, for peptide H no fluores-
cence change is observed after auranofin addition (Fig. 4B). This
finding is indicative of no significant variation of Trp31 environ-
ment and suggests a tighter binding of Zn to peptide H.
3.5. NMR study
Preliminary 1H NMR studies were performed on peptide A and
peptide H. Both apopeptides were unstructured in phosphate
buffer at pH 7.2, whereas the formation of the zinc finger inducesnium acetate (pH = 7), ZnCl2 (molar ratio peptide:ZnCl2 = 1:1.2) after 1 h incubation
were calculated from +4 and +3 charged ions indicated by labels in the right panels
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nances in the spectra and good quality 2D-NMR spectra (Figs. S3
and S4). For both peptides we recorded also spectra in presence
of auranofin. The 1D-NMR spectra of the peptides recorded 24 h
after the addition of auranofin resemble those of the apopeptides.
In addition, the absence of significant NOEs in NOESY and ROESY
spectra recorded at different times after auranofin addition pre-
cluded further structural characterization of the gold complexes
by NMR (data not shown).
3.6. Mass spectrometry
ESI-MS spectrometric analysis was used to gain additional evi-
dence on the interaction of peptide A and peptide H with aura-
nofin. First, an aliquot of auranofin, 6.5 mM in methanol, was
analysed by MALDI mass spectrometry (Fig. S5). The observed
molecular mass at m/z 993.1 is due to an auranofin molecule
bound to an Au-P(CH2CH3)3 group, probably via the sulfur atom.
The molecular ion at m/z 1553.1 was attributed to an adduct
formed by two auranofin molecules bound via an additional Au+
ion that eventually links the sulfur atoms of the auranofin mole-
cules (Au-Au bonds should be considered). Finally, the two mass
ions at m/z 977.1 and 1537.1 displayed a mass difference of
16 Da from signals at m/z 993.1 and 1553.1, respectively; this dis-
crepancy may be accounted for by a possible presence of trace
impurity in the commercial sample.
The formation of the peptide-auranofin complexes was investi-
gated by ESI-MS analyses. Auranofin was added to the apopeptide
solutions in the presence of the non-thiol reducing agent TCEP. ESI-
MS analysis was carried out on a time course basis by recording
spectra at different incubation times (0 h, 24 h, 48 h, 1 week and
1 month). Fig. S6 shows the results obtained after one month incu-
bation time for peptide A and peptide H. Mass signals atm/z 3220.3
and 3194.3 were assigned to the peptide A and peptide H com-
plexed with Au+, respectively. This may be due to the Au+ ion bind-
ing to the first two cysteines of the peptide; however, the other
two isomers cannot be excluded. These complexes were not
observed at shorter incubation times, in the range 1–7 days.
MS was also used to study the displacement of the zinc ion from
the zinc finger peptides upon addition of auranofin. The ESI-MS
spectrum of peptide A, after one hour from the addition of the zinc
ion, shows a mass signal at m/z 3087.2 corresponding to the pep-
tide complexed to zinc (Fig. S7A). A corresponding complex dis-
playing molecular mass of 3062.7 was observed in the case of
peptide H (Fig. S7B). Auranofin was then added to both peptide
complexes and the ESI-MS spectra were recorded at different incu-
bation times in the range 10 min–3 weeks. In the case of the zinc
finger of peptide A, after one hour of incubation with auranofin
the ESI-MS spectra demonstrated the presence of the reduced pep-
tide A (MWav: 3024.9), the peptide-zinc ion complex (MWav:
3087.5), the peptide-Au+ complex (MWav: 3220.6) and the pep-
tide-Au-triethylphosphine complex (MWav: 3338.6) (Fig. 5A).
The corresponding species were also observed in the case of the
zinc finger of peptide H after one hour of incubation with average
masses of 2999.3, 3062.6, 3195.2 and 3313.1, respectively (Fig. 5B).
The peaks corresponding to all the above mentioned peptide spe-
cies were observed in all the ESI-MS spectra taken after incubation
times of 24 h, 4 days, 1 week, 2 weeks and 3 weeks for peptide A
(Figs. S8A–S12A). In the case of peptide H, all the species were also
observed in the spectrum registered after 24 h of incubation. On
the contrary, the molecular mass corresponding to the peptide
H-Au-triethylphosphine complex was never found in the ESI-MS
spectra measured after 4 days, 1 week, 2 weeks and 3 weeks
(Figs. S8B–S12B).
Two conclusions can be drawn. First, the complexes of the two
peptides with gold are initially observed at considerably shortertimes when the zinc ions are present, suggesting a possible ‘‘cat-
alytic” role of the zinc ions. Second, the peptides show different
binding characteristics, since the peptide-Au-triethylphosphine
complex is always found in peptide A but not in peptide H.4. Discussion
Auranofin has been used in the treatment of rheumatoid arthri-
tis and psoriatic arthritis. In this context, Shapiro and Masci [32]
observed that an HIV-1 patient treated with auranofin for psoriatic
arthritis, but not with anti-retroviral therapy, showed a significant
increase in CD4+ lymphocyte count, thus suggesting that auranofin
had caused the improvement in the patient’s conditions. Recently,
it has also been found that a combined anti-retroviral and aura-
nofin therapy in rhesus macaques infected with a HIV simian
homolog, is able to maintain a reduced viral titre long-term after
treatment withdrawn [18]. Noteworthy, other aurothiolates
derivatives of gold (I) (aurothioglucose and aurothiomalate) inhibit
the HIV-1 infectivity in vitro by activating gold(I) ligand exchange
between the reactive species bis(thiolate) gold(I) and acidic thiol
groups exposed on the surface of virion proteins [33]. A different
mechanism has been recently proposed, whereby auranofin could
target the infected cells (T-lymphocytes) through the inhibition
of reduction/oxidation (redox) enzymes such as thioredoxin reduc-
tase and subsequent induction of cell apoptosis [34].
Our results suggest that auranofin, and eventually other auroth-
iolate drugs, could also modulate and/or inhibit the HIV nucleocap-
sidic protein. Themechanism of coordination and zinc ejection from
NC due to aurothiolate drugs (gold(I)) could be the same described
in a study of the interactions of Gold(I)-Phosphine-N-Heterocycle
compounds with the C-terminal HIVNCp7 zinc finger [7].
ESI-MS analyses have unequivocally shown that: (i) peptide
complexes with Au are formed slowly when the apopeptides are
allowed to react with auranofin (Fig. S6); (ii) the formation of com-
plexes is fast when the zinc-bound peptides are used. In fact, we
observed an Et3P-Au-peptide complex in a first reaction step with
both the studied peptides and an Au-peptide complex produced in
a second reaction step via displacement of PEt3 (Fig. 5). However,
we have no evidence of an Au2-peptide complex, as reported in
the previously cited investigation [7]. The chemistry of gold(I)
complexes is dominated by linear two-coordinate complexes of
the form ligand1-Au-ligand2 [35]. In our case a complex is formed
with two cysteines but we cannot distinguish between the possible
different isomers due to the presence of three cysteines. Therefore,
we cannot ascertain if we are dealing with a single isomer or a mix-
ture. In addition, different isomers could be formed depending on
the specific experimental conditions.
Possible reasons of the slower reactivity of the apopeptides
could be both the absence of a structural preorganization induced
by zinc binding and the protonation state of the cysteines. In the
apopeptides cysteines are predominantly in the thiol form,
whereas in the zinc finger the thiolate form is likely present
[36,37]. According to the Hard/Soft Acid/Base (HSAB) theory, sulfur
is a relatively soft and polarizable atom; Au+ and Zn2+ are a soft and
a borderline ion, respectively [38]. Upon ionization of the thiol (i.e.,
SH? S), the consequent expansion of the anionic cloud increases
the softness and yields the easily polarizable thiolate nucleophile.
Consequently, the soft electrophile Et3PAu+ competes favorably
with the Zn2+ ions for the thiolate and the exchange occurs. The
Zn-bound thiolates of the zinc fingers have been reported to have
different susceptibility to electrophilic attack that depend on the
specific Cys residue [39,40].
These characteristics, together with conformational sequence-
related peculiarities, may lead to differences in the complexation
properties of the zinc finger peptides with zinc or other metals.
338 M.A. Castiglione Morelli et al. / Inorganica Chimica Acta 453 (2016) 330–338In the MS experiments we observe the same type of complexes
for peptides A and H, but some differences were found. The most
significant one is the disappearance of the peptide H-Au-tri-
ethylphosphine signal after 4 days of incubation with the drug,
while peptide A shows the corresponding signal for the entire
time-span investigated.
The results of the spectroscopic investigations are less straight-
forward to interpret. In CD spectra of peptide H no substantial
change in the zinc finger structure is observed upon auranofin
addition (Fig. 2B); besides, for zinc-bound peptide H no change
was noticed in fluorescence spectra when auranofin is added
(Fig. 4B). Furthermore, absorption spectroscopy data in presence
of PAR indicate that peptide H forms readily a zinc complex by dis-
placement of Zn2+ from PAR and that Au+ is able to displace quickly
Zn2+ (Fig. 3B). On the contrary, zinc-bound peptide A interacts with
Au+ on a short time-scale as evidenced by the marked effect both in
CD (Fig. 2A) and in fluorescence spectra (Fig. 4A) upon auranofin
addition. However, in presence of PAR, peptide A binds slowly to
Zn2+ and Au+ is apparently able to displace Zn2+ (Fig. 3A).
Taken together, our results indicate that the peptide-zinc com-
plexes from two different isolates of HIV-2, in appropriate condi-
tions, can react with the drug auranofin by forming gold
complexes, while the apopeptides form gold complexes as well,
but slowly. In addition, our results show that the reactivity of the
zinc finger towards auranofin can be influenced by the specific
amino acid sequence. Therefore, we suggest that the HIV nucleo-
capsidic protein could be considered as a potential target of
auranofin.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.ica.2016.08.012.
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